United Historical Financial Ratios

UTHR Stock

USD 378.13 1.13 0.30%

United Therapeutics is promptly reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114, PTB Ratio of 1.63 or Days Sales Outstanding of 84.52 will help investors to properly organize and evaluate United Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

About United Financial Ratios Analysis

United TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate United Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on United financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across United Therapeutics history.

United Therapeutics Financial Ratios Chart

At this time, United Therapeutics' Net Income Per Share is relatively stable compared to the past year. As of 11/29/2024, Payables Turnover is likely to grow to 48.28, while PTB Ratio is likely to drop 1.63.

Price To Sales Ratio Dividend Yield Ptb Ratio Days Sales Outstanding Book Value Per Share Average Payables

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing United Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on United Therapeutics sales, a figure that is much harder to manipulate than other United Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is United Therapeutics dividend as a percentage of United Therapeutics stock price. United Therapeutics dividend yield is a measure of United Therapeutics stock productivity, which can be interpreted as interest rate earned on an United Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from United Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into United Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.At this time, United Therapeutics' Net Income Per Share is relatively stable compared to the past year. As of 11/29/2024, Payables Turnover is likely to grow to 48.28, while PTB Ratio is likely to drop 1.63.

	2023	2024 (projected)
Dividend Yield	0.0129	0.0114
Price To Sales Ratio	4.42	4.2

Dividend Yield Price To Sales Ratio

United Therapeutics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding
Price To Sales Ratio		0.1	0.61	0.99	-0.39	-0.7	-0.41	0.15	-0.62	0.61	1.0	-0.39	-0.93	-0.36	-0.41	0.64	-0.34	-0.8	1.0	-0.38	-0.51	-0.94	0.1	-0.34	-0.57	0.95
Dividend Yield	0.1		0.37	0.0	-0.68	-0.14	-0.52	0.36	-0.54	0.37	0.1	-0.44	-0.04	0.01	-0.6	0.32	-0.71	0.5	0.09	-0.57	0.05	-0.03	1.0	-0.28	-0.07	0.16
Ptb Ratio	0.61	0.37		0.6	-0.71	-0.39	-0.44	0.34	-0.75	1.0	0.61	-0.34	-0.42	-0.21	-0.39	0.54	-0.48	-0.32	0.6	-0.66	0.11	-0.47	0.37	-0.14	0.02	0.6
Days Sales Outstanding	0.99	0.0	0.6		-0.35	-0.68	-0.37	0.14	-0.58	0.6	0.99	-0.35	-0.92	-0.39	-0.36	0.64	-0.3	-0.86	0.99	-0.35	-0.5	-0.93	0.01	-0.3	-0.55	0.94
Book Value Per Share	-0.39	-0.68	-0.71	-0.35		0.28	0.74	-0.75	0.63	-0.71	-0.39	0.65	0.23	-0.07	0.74	-0.35	0.91	-0.03	-0.38	0.98	0.09	0.29	-0.69	0.24	0.2	-0.51
Free Cash Flow Yield	-0.7	-0.14	-0.39	-0.68	0.28		0.74	-0.08	0.59	-0.39	-0.7	0.77	0.8	0.37	0.63	-0.52	0.28	0.52	-0.7	0.24	0.72	0.72	-0.14	0.76	0.71	-0.65
Operating Cash Flow Per Share	-0.41	-0.52	-0.44	-0.37	0.74	0.74		-0.52	0.62	-0.44	-0.41	0.99	0.45	0.04	0.93	-0.31	0.72	0.07	-0.4	0.71	0.54	0.43	-0.53	0.68	0.57	-0.5
Average Payables	0.15	0.36	0.34	0.14	-0.75	-0.08	-0.52		-0.34	0.34	0.15	-0.46	-0.03	0.02	-0.51	0.22	-0.77	0.04	0.15	-0.83	-0.27	-0.06	0.36	-0.31	-0.35	0.25
Capex To Depreciation	-0.62	-0.54	-0.75	-0.58	0.63	0.59	0.62	-0.34		-0.75	-0.62	0.5	0.56	0.42	0.62	-0.69	0.52	0.23	-0.61	0.56	0.23	0.52	-0.54	0.6	0.35	-0.64
Pb Ratio	0.61	0.37	1.0	0.6	-0.71	-0.39	-0.44	0.34	-0.75		0.61	-0.34	-0.42	-0.21	-0.39	0.54	-0.48	-0.32	0.6	-0.66	0.11	-0.47	0.37	-0.14	0.02	0.6
Ev To Sales	1.0	0.1	0.61	0.99	-0.39	-0.7	-0.41	0.15	-0.62	0.61		-0.39	-0.93	-0.36	-0.41	0.64	-0.34	-0.8	1.0	-0.38	-0.51	-0.94	0.1	-0.34	-0.57	0.95
Free Cash Flow Per Share	-0.39	-0.44	-0.34	-0.35	0.65	0.77	0.99	-0.46	0.5	-0.34	-0.39		0.46	0.0	0.9	-0.24	0.65	0.1	-0.38	0.63	0.61	0.44	-0.44	0.68	0.61	-0.47
Roic	-0.93	-0.04	-0.42	-0.92	0.23	0.8	0.45	-0.03	0.56	-0.42	-0.93	0.46		0.3	0.5	-0.49	0.2	0.77	-0.94	0.21	0.65	0.97	-0.04	0.48	0.68	-0.87
Inventory Turnover	-0.36	0.01	-0.21	-0.39	-0.07	0.37	0.04	0.02	0.42	-0.21	-0.36	0.0	0.3		-0.1	-0.82	0.11	0.36	-0.35	-0.11	0.22	0.17	0.01	0.42	0.23	-0.32
Net Income Per Share	-0.41	-0.6	-0.39	-0.36	0.74	0.63	0.93	-0.51	0.62	-0.39	-0.41	0.9	0.5	-0.1		-0.18	0.68	0.03	-0.41	0.7	0.51	0.49	-0.61	0.62	0.57	-0.49
Days Of Inventory On Hand	0.64	0.32	0.54	0.64	-0.35	-0.52	-0.31	0.22	-0.69	0.54	0.64	-0.24	-0.49	-0.82	-0.18		-0.46	-0.38	0.64	-0.3	-0.28	-0.39	0.32	-0.45	-0.36	0.61
Payables Turnover	-0.34	-0.71	-0.48	-0.3	0.91	0.28	0.72	-0.77	0.52	-0.48	-0.34	0.65	0.2	0.11	0.68	-0.46		-0.08	-0.34	0.89	0.26	0.21	-0.71	0.35	0.36	-0.49
Average Inventory	-0.8	0.5	-0.32	-0.86	-0.03	0.52	0.07	0.04	0.23	-0.32	-0.8	0.1	0.77	0.36	0.03	-0.38	-0.08		-0.81	0.02	0.48	0.79	0.49	0.15	0.45	-0.73
Capex To Revenue	1.0	0.09	0.6	0.99	-0.38	-0.7	-0.4	0.15	-0.61	0.6	1.0	-0.38	-0.94	-0.35	-0.41	0.64	-0.34	-0.81		-0.37	-0.51	-0.94	0.09	-0.33	-0.57	0.95
Cash Per Share	-0.38	-0.57	-0.66	-0.35	0.98	0.24	0.71	-0.83	0.56	-0.66	-0.38	0.63	0.21	-0.11	0.7	-0.3	0.89	0.02	-0.37		0.14	0.28	-0.58	0.22	0.24	-0.5
Pocfratio	-0.51	0.05	0.11	-0.5	0.09	0.72	0.54	-0.27	0.23	0.11	-0.51	0.61	0.65	0.22	0.51	-0.28	0.26	0.48	-0.51	0.14		0.55	0.05	0.76	0.98	-0.49
Interest Coverage	-0.94	-0.03	-0.47	-0.93	0.29	0.72	0.43	-0.06	0.52	-0.47	-0.94	0.44	0.97	0.17	0.49	-0.39	0.21	0.79	-0.94	0.28	0.55		-0.03	0.33	0.59	-0.89
Payout Ratio	0.1	1.0	0.37	0.01	-0.69	-0.14	-0.53	0.36	-0.54	0.37	0.1	-0.44	-0.04	0.01	-0.61	0.32	-0.71	0.49	0.09	-0.58	0.05	-0.03		-0.28	-0.07	0.16
Capex To Operating Cash Flow	-0.34	-0.28	-0.14	-0.3	0.24	0.76	0.68	-0.31	0.6	-0.14	-0.34	0.68	0.48	0.42	0.62	-0.45	0.35	0.15	-0.33	0.22	0.76	0.33	-0.28		0.79	-0.34
Pfcf Ratio	-0.57	-0.07	0.02	-0.55	0.2	0.71	0.57	-0.35	0.35	0.02	-0.57	0.61	0.68	0.23	0.57	-0.36	0.36	0.45	-0.57	0.24	0.98	0.59	-0.07	0.79		-0.56
Days Payables Outstanding	0.95	0.16	0.6	0.94	-0.51	-0.65	-0.5	0.25	-0.64	0.6	0.95	-0.47	-0.87	-0.32	-0.49	0.61	-0.49	-0.73	0.95	-0.5	-0.49	-0.89	0.16	-0.34	-0.56

Click cells to compare fundamentals

United Therapeutics Account Relationship Matchups

United Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Price To Sales Ratio	2.66	4.52	5.76	6.53	4.42	4.2
Ptb Ratio	1.39	1.98	2.45	2.64	1.72	1.63
Days Sales Outstanding	38.14	38.73	43.03	41.55	43.74	84.52
Book Value Per Share	63.48	76.81	88.17	105.42	127.88	134.27
Free Cash Flow Yield	(0.0752)	0.1	0.0492	0.0525	0.0726	0.0763
Operating Cash Flow Per Share	(4.72)	17.1	13.32	17.64	20.9	21.94
Stock Based Compensation To Revenue	0.0313	0.11	0.0822	0.0552	0.0168	0.016
Capex To Depreciation	1.82	1.19	2.42	2.71	4.33	5.24
Pb Ratio	1.39	1.98	2.45	2.64	1.72	1.63
Ev To Sales	2.74	4.56	5.7	6.45	4.2	3.99
Free Cash Flow Per Share	(6.63)	15.76	10.63	14.59	15.97	16.77
Inventory Turnover	1.26	1.25	1.31	1.44	2.3	1.19
Net Income Per Share	(2.39)	11.65	10.6	15.98	21.04	22.09
Days Of Inventory On Hand	289.89	292.07	279.49	253.78	158.47	150.55
Payables Turnover	11.88	26.37	32.24	35.78	45.98	48.28
Sales General And Administrative To Revenue	0.13	0.19	0.25	0.21	0.17	0.16
Capex To Revenue	0.11	0.0578	0.04	0.0717	0.099	0.094
Cash Per Share	32.55	33.92	41.52	62.39	63.98	67.18
Pocfratio	(18.67)	8.88	16.22	15.77	10.52	5.36
Interest Coverage	(4.24)	25.26	29.89	30.24	19.98	20.98
Capex To Operating Cash Flow	0.24	(0.41)	0.0785	0.2	0.17	0.25
Pfcf Ratio	(13.29)	9.63	20.32	19.06	13.77	13.08
Days Payables Outstanding	30.73	13.84	11.32	10.2	7.94	7.54
Income Quality	1.32	1.98	1.47	1.26	1.1	0.99
Roe	0.21	(0.0376)	0.15	0.12	0.16	0.17
Ev To Operating Cash Flow	(19.21)	8.96	16.06	15.57	10.0	5.78
Pe Ratio	(36.92)	13.03	20.39	17.4	10.45	12.14
Ev To Free Cash Flow	(13.67)	9.72	20.12	18.82	13.09	12.43
Earnings Yield	(0.0271)	0.0767	0.049	0.0575	0.0957	0.1
Intangibles To Total Assets	0.0405	0.0343	0.008628	0.007362	0.0159	0.0151
Net Debt To E B I T D A	(1.49)	0.0948	(0.13)	(0.15)	(0.37)	(0.35)
Current Ratio	4.03	6.7	7.61	9.85	4.41	7.29
Tangible Book Value Per Share	59.87	73.24	87.18	104.44	125.44	131.71
Receivables Turnover	9.57	9.42	8.48	8.79	8.35	5.55
Graham Number	58.38	141.88	144.99	194.72	246.06	258.36
Shareholders Equity Per Share	63.48	76.81	88.17	105.42	127.88	134.27

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.64	EWTX	Edgewise Therapeutics	Pair Corr
0.65	BHC	Bausch Health Companies	Pair Corr

Moving against United Stock

0.7	HLN	Haleon plc	Pair Corr
0.67	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.65	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.65	ZTS	Zoetis Inc	Pair Corr
0.57	LLY	Eli Lilly Sell-off Trend	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

United Historical Financial Ratios

About United Financial Ratios Analysis

United Therapeutics Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ptb Ratio

Book Value Per Share

Average Payables

United Therapeutics fundamentals Correlations

United Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

United Therapeutics fundamentals Accounts

Pair Trading with United Therapeutics

Moving together with United Stock

Moving against United Stock

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Payout Ratio	+ 1.0	Dividend Yield
Pb Ratio	+ 1.0	Ptb Ratio
Capex To Revenue	+ 1.0	Ev To Sales
Days Sales Outstanding	+ 0.99	Price To Sales Ratio

Interest Coverage	- 0.94	Capex To Revenue
Capex To Revenue	- 0.94	Roic
Interest Coverage	- 0.94	Ev To Sales
Interest Coverage	- 0.94	Price To Sales Ratio
Roic	- 0.93	Ev To Sales
Interest Coverage	- 0.93	Days Sales Outstanding